Galecto to Present Two Posters at AACR Annual Meeting 2023
“We are very pleased to be presenting this data at AACR as it demonstrates the potential anti-cancer effects of both our galectin-1 specific inhibitor and our dual acting galectin-1/3 inhibitor,” said Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of
Details for the poster presentations are as follows:
Title: Preclinical evaluation of the role of Galectin-1 in tumor immune evasion associated mechanisms using highly selective Galectin-1 small molecule inhibitor
Location: Poster Section 35
Poster Number: 20
Title: A bioinformatics approach to determine the potential benefit of blocking both Galectin-1 and Galectin-3 in cancer
Location: Poster Section 34
Poster Board Number: 6
Following presentation at the AACR Annual Meeting, these posters will be available on the Scientific Conferences page of Galecto’s investor relations website at https://ir.galecto.com/news-and-events/scientific-events.
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a recently completed Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq®) in a separate Phase 2 trial for the treatment of non-small cell lung cancer.
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s ability to make progress across its clinical pipeline of assets and the potential efficacy of Galecto’s galectin-1 and galectin-3 inhibitor product candidates. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements,
|For more information, contact:
|Hans Schambye, CEO|
|+45 70 70 52 10|
|+1 617 430 7577||+41 78 680 0538|
Source: Galecto, Inc.